Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide versus placebo for metabolic profile in type 2 diabetes mellitus with cardiovascular disease
2017-005032-42Phase 3Terminated
- Sponsor
- RWTH Aachen University
- Start
- Feb 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of liraglutide in type 2 diabetes mellitus (T2DM) and cardiac morbidity (2 arms), sponsored by RWTH Aachen University. Primary endpoint: Metabolic profile. Started Feb 2020; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2017-005032-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005032-42.